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  26 
Summary 27 
Over the past decade stem cell research has emerged as an area of major interest for its 28 
potential in regenerative medicine applications. This is in constant need of new cell sources to 29 
conceive regenerative medicine approaches for diseases that are still without therapy. 30 
Scientists drew the attention toward alternative sources such as foetal adnexa and fluid, since 31 
these sources possess many advantages: first of all, cells can be extracted from discarded 32 
foetal material and it is noninvasive for the patient and inexpensive, secondly abundant stem 33 
cells can be obtained and finally, these stem cell sources are free from ethical considerations. 34 
Cells derived from foetal adnexa and fluid preserve some of the characteristics of the 35 
primitive embryonic layers from which they originate. Many studies have demonstrated the 36 
differentiation potential in vitro and in vivo toward mesenchymal and non-mesenchymal cell 37 
types; in addition the immune-modulatory properties make these cells a good candidate for 38 
allo- and xenotransplantation. Naturally occurring diseases in domestic animals can be more 39 
ideal as disease model of human genetic and acquired diseases and could help to define the 40 
potential therapeutic use efficiency and safety of stem cells therapies. This review offers an 41 
update on the state of the art of characterization of domestic animals MSCs derived from 42 
foetal adnexa and fluid and on the latest findings in pre-clinical or clinical setting of the stem 43 
cell populations isolated from these sources. 44 
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  47 
Introduction 48 
 49 
A stem cell is an undifferentiated cell capable of differentiating into specialized cells and to 50 
originate other stem cells. In mammals, there are three types of stem cells (SCs): embryonic 51 
stem cells (ESCs), foetal stem cells, and adult stem cells. ESCs derive from the inner cell 52 
mass (ICM) of a blastocyst. They are pluripotent but highly tumorigenic after transplantation. 53 
Foetal stem cells are distinguished into two types: foetal proper stem cells (from the tissue of 54 
the fetus), and extra-embryonic foetal stem cells (from extra-embryonic membranes). Adult 55 
SCs are multipotent cells, designate to tissue repairing, and they are present in almost all adult 56 
tissues. 57 
Mesenchymal stem cells (MSCs) are a population of multipotent stem cells that meet the 58 
following criteria: 1) plastic-adherence when maintained in standard culture conditions; 2) 59 
expression of CD105, CD73 and CD90, and lack of CD45, CD34, CD14 or CD11b, CD79α 60 
or CD19 and HLA-DR surface molecules; 3) differentiation to osteoblasts, adipocytes and 61 
chondroblasts in vitro (Dominici et al. 2006). 62 
Since these properties, MSCs offer a great chance for cell-based therapies and tissue 63 
engineering applications. The effective management of companion animals, such as dog, cat 64 
or horse, requires sophisticated new treatments and preventive strategies. This, combined with 65 
their role as models for human diseases, led to an increase in the number of research focused 66 
on isolation and clinical use of MSCs in these animals. 67 
Bone marrow (BM) is the common source of autologous MSCs for clinical applications in 68 
veterinary medicine. Alternatively, adipose tissue-derived MSCs can be used, since they have 69 
a higher proliferation potential. Anyway, for both sources, an invasive procedure is required 70 
and there is a large variability in the cell yield related to the donor (Colleoni et al. 2009). 71 
Placental tissues and foetal fluids represent a source of cells for regenerative medicine, and 72 
are readily available and easily procured without invasive procedures. MSCs from foetal 73 
fluids and adnexa are defined as an intermediate between ESCs and adult SCs, due to the 74 
preservation of some characteristics typical of the primitive native layers. Among foetal 75 
adnexal tissues, the major sources of MSCs are amnion, amniotic fluid, umbilical cord and 76 
umbilical cord blood. These cells can be obtained in large numbers without risks for donors 77 
and cryopreserved for future use in regenerative veterinary medicine. 78 
The markers required for defining a MSC were determined for human cells, and the lack of 79 
specific antibodies for different animal species lead to a great variability of approaches and 80 
results for molecular characterization of animal MSCs. The aim of this review is to provide an 81 
overview of the advances in characterization and clinical applications of domestic animal 82 
MSCs derived from foetal adnexa and fluid. 83 
 84 
Developmental biology of foetal adnexa and amniotic fluid 85 
 86 
Extra-embryonic or foetal membranes are structures that develop from the zygote, do not 87 
form part of the embryo itself, and are of functional importance only in embryonic life. At the 88 
end of cleavage, the blastocysts, enclosed within the zona pellucida, consists of an ICM and a 89 
trophoblastic layer. During the second week of development, hatched blastocyst leaves its 90 
confined space and elongates. In particular this process involves the trophoblast, and, 91 
partially, the inner endodermal lining. The head and tail of growing embryo, progressively, 92 
push deeper in to the trophoblast, which become lined by a layer of somatic mesoderm 93 
forming the extra-embryonic somatopleure (McGeady et al. 2006). The outer somatopleure 94 
membrane forms chorion, while the inner somatopleure membrane, attached to the embryos at 95 
umbilicus, forms amnion. Due to its early development, amnion could be a reservoir of 96 
pluripotent stem cells, derived from the contiguity of embryonic epiblast, even at full term 97 
pregnancy. Amnion is a thin, tough, membranous and fluid-filled sac which surrounds and 98 
protects the embryo and then the foetus (McGeady et al. 2006). When first formed, it is in 99 
contact with the embryo’s body, but, after few weeks of pregnancy, fluid begins to 100 
accumulate within it. This fluid increases in quantity relatively rapidly up to mid-pregnancy 101 
and then gradually decreases. In early pregnancy, the composition of amniotic fluid and 102 
plasma are similar and may be considered a dialysate of the maternal or foetal extracellular 103 
fluid. Later in gestation, when the foetus urethra becomes patent, foetal urine passes in 104 
amniotic cavity. Amniotic fluid (AF) contains less than 2% of solids, consisting of urea and 105 
other extractives, inorganic salts, a small amount of protein, a trace of sugar and multiple cell 106 
types from embryonic and extra-embryonic tissues (Gosden 1983).  107 
With the progress of gestation, the embryo sinks into the amniotic membrane (AM), which 108 
wraps the mesoblastic axis in which allantois and umbilical vessels developed, giving rise to 109 
the umbilical cord (UC) (Barone 1994). Based on structural and functional studies, at least 110 
four distinctive zones are now recognized in the UC: surface amniotic epithelium, 111 
subamniotic stroma, perivascular stroma, vessels. All together these structures are called 112 
umbilical cord matrix (UCM). The connective tissue included between subamnion and 113 
perivascular regions consists of mucous, mesenchymal connective tissue, and it is called 114 
Wharton's jelly (WJ). It contains a very low number of cells and a high amount of 115 
extracellular matrix components, such as collagen, hyaluronic acid and proteoglycans 116 
(Sobolewski et al. 1997). These substances make this tissue highly hydrated and resistant to 117 
extension and compression evoked by foetal movements and uterine contraction. Stromal 118 
cells of WJ, previously described as myofibroblast (Takechi et al. 1993), have properties of 119 
potentially multipotent SCs (Mitchell et al. 2003). 120 
 121 
Amniotic membrane 122 
 123 
After mechanically separating amnion from allantois, as in human medicine, it is possible to 124 
harvest two cellular types, amniotic epithelial (AECs) or mesenchymal cells (AMSCs). AECs 125 
have a typical polygonal morphology while AMSCs are fibroblast-like. Both AMSCs and 126 
AECs from different species have been investigated for proliferative potential, differentiation 127 
ability, and phenotypically characterized. 128 
AECs showed similar patterns to AMSCs in the sheep (Gloria et al. 2010; Mauro et al. 2010; 129 
Mattioli et al. 2012), but the latter were superior in promoting interbody fusion in induced 130 
anterior cervical discectomy after allogenic implantation combined with bone grafts 131 
(Goldschlager et al. 2011). AECs phenotype, methylation status, immunomodulatory and 132 
stemness properties are affected by gestational age (Barboni et al. 2014). In the horse (Lange-133 
Consiglio et al. 2012) and in the bovine (Corradetti et al., 2013), AECs showed a lower 134 
number of doublings compared to AMSCs but the same phenotype and plasticity at 135 
differentiation. Feline AECs were fully characterized and were able to differentiate into 136 
adipogenic, chondrogenic, osteogenic and neurogenic lineages (Rutigliano et al. 2013). 137 
Porcine AECs were successfully used for construction of tissue-engineered cornea (Luo et al. 138 
2013). 139 
Focusing on MSCs, they express pluripotency and mesenchymal markers, have a multi-140 
lineage differentiation potential and possess a privileged immunogenic status related to the 141 
low expression or even absent levels of MHC I and MHC II (data are summarized in Table 1).  142 
AMSCs were capable of inhibiting peripheral blood mononuclear cell proliferation after 143 
allogenic stimulation either when co-cultured in cell-to-cell contact or when separated by a 144 
transwell membrane (Lange-Consiglio et al. 2013b). Furthermore, it was demonstrated that 145 
AMSCs possess nonteratogenicity 4 weeks post injection into immunodeficient mice (Vidane 146 
et al. 2014). 147 
Comparing results from different species, among pluripotency markers, a difference was 148 
found for NANOG expression. While in the horse (Violini et al. 2012) and buffalo (Dev et al. 149 
2012; Mann et al. 2013) AMSCs expressed NANOG at RT-PCR, canine AMSCs were 150 
negative (Filioli Uranio et al. 2011, 2014). Anyway, Park et al. (2012) could quantified it in 151 
canine AMSCs using qPCR.  152 
Mesenchymal markers were expressed in all species while haematopoietic markers were not 153 
found. In the horse, CD34 was not expressed in early stages of culture, but began to be 154 
expressed at later passages (P5) (Lange-Consiglio et al. 2013a). By the way, the consensus 155 
about absence of CD34 expression on MSCs has been challenged. The CD34 expression 156 
status in haematopoietic and MSCs appears to depend on the environment, and can change 157 
from positive to negative, and vice versa (Lin et al. 2012). 158 
Karyotype of cultured AMSCs was confirmed to be stable in the dog (Filioli Uranio et al. 159 
2011, 2014), buffalo (Dev et al. 2012c; Mann et al. 2013) and horse (Seo et al. 2013). In the 160 
dog, a high telomerase activity was found (Filioli Uranio et al. 2011). Telomerase activity and 161 
telomere maintenance characterize all cells with self-renewal capability, such as ESCs, MSCs, 162 
and most cancer cells (Colosimo et al. 2013a).  163 
 164 
Amniotic fluid 165 
In the veterinary field, as in the human, AF contains a heterogeneous population of cells: 166 
cuboidal epitheloid (E-cells), round (R-cells) and spindle-shaped fibroblastic (F-cells) cells. 167 
E-cells probably derive from foetal skin and urine and they are lost during the first passages 168 
of culture; R-cells are supposed to originate from foetal membranes and trophoblasts; F-cells 169 
are generated from mesenchymal tissues and are supposed to be the MSC population of the 170 
AF (Klemmt et al. 2011). In domestic animals, the prevalent cell population that persist 171 
during culture is the F-type, except for one study on porcine AFMSCs (Sartore et al. 2005) 172 
and one on bovine AFMSCs (Rossi et al. 2014), where both F-cells and R-cells persist 173 
through passages. Other groups, that studied bovine AF cell populations (Corradetti et al. 174 
2013; Gao et al. 2014; da Cunha et al. 2014), found R-cells only at the very first passages, 175 
maybe due to the addition in the culture medium of growth factors like EGF and bFGF. 176 
AFMSCs generally express MSC markers and mesodermal markers like Vimentin and α-177 
Smooth Muscle Actin (αSMA) and are negative for haematopoietic markers (Table 2). In the 178 
horse, expression of CD73 is controversy. Positivity was found only for AD2 clone, while 179 
clone 5F/B9 did not cross-react (Gulati et al. 2013). Anyway, for AD2 clone cross-reactivity 180 
was not found in equine (Iacono et al. 2012a) and also in feline (Iacono et al. 2012b) and 181 
bovine AFMSCs (Rossi et al. 2014). Like AMSCs, also AFMSCs express pluripotency 182 
markers and only in one study in the bovine (Rossi et al. 2014) expression of OCT4, NANOG 183 
and SOX2 was not found. 184 
Different authors verified that AFMSCs show telomerase activity and that telomere length is 185 
not affected by culture conditions (Filioli Uranio et al. 2011; Colosimo et al. 2013a), such as 186 
karyotype (Filioli Uranio et al. 2011; Dev et al. 2012a; Dev et al. 2012b; Colosimo et al. 187 
2013b; Weber et al. 2013; da Cunha et al. 2014). 188 
 189 
Umbilical cord blood (UCB) 190 
 191 
In human medicine, the use of UCB as a source of MSCs can be traced back to 2000: in this 192 
year Erices et al. showed that UCB cells were able to give rise to two types of adherent cells, 193 
one of which expressed antigens typical of MSCs. Also in veterinary medicine cells with 194 
characteristics similar to human UCBMSCSs have been isolated in different species (Table 3). 195 
Usually, an isolation rate of fibroblast-like, spindle-shaped cells, similar to human, between 196 
50 and 70% is reported (Koch et al. 2007; Iacono et al. 2012a; Mohanty et al. 2014), except 197 
for feline UCB where cells at P0 comprised a heterogeneous population, including fibroblast-198 
like, spindle-shaped, and small round morphologies (Jin et al. 2008). Reported data may be 199 
due to the limited number of MSCs in UCB as well as suboptimal isolation and expansion 200 
conditions. In horses was demonstrated that samples cultured at 5% O2 proliferated rapidly to 201 
the desired cell number. The effect of mild hypoxia may be attributable in part to the 202 
induction of signaling pathways but also to a decrease in survival of contaminating leukocytes 203 
in UCB, thus increasing the isolation rate up to 80% (Schuh et al. 2009). Furthermore, 204 
particularly in equine species, the UCB recovered volume is often low, because of a wide 205 
spread belief that the mare continues to pass blood to the foal through the umbilicus 206 
immediately post foaling (Rossdale 1958). However, using Doppler ultrasound, Doarn (1985) 207 
showed that blood flow through the cord ceases within few minutes following delivery. All 208 
authors reported that UCBMSCs cells from domestic animals sources were positive for CD44 209 
(Table 3), an antigen expressed by a variety of cells types, not part of the ISCT MSC 210 
definition (Dominici et al. 2006). Given its constant expression and considering the difficulty 211 
in UCBMSCs isolation, sorting of CD44+ cells prior to plastic adherence isolation could lead 212 
to more homogenous populations in domestic animals (Paebst et al. 2014). A variability of the 213 
other MSCs marker expression exists particularly for CD73. Similarly to AFMSCs, in the 214 
horse only Mohanty et al. (2014) showed that UCBMSCs expressed CD73, both with RT-215 
PCR and flow cytometry. Authors explained their finding with the use of different CD73 216 
clones (5F/B9), compared with a previous study reporting its negative expression (De 217 
Schauwer et al. 2012; 10fl clone). However, Mohanty’s research group stated that equine 218 
AFMSCs reacted with AD2 clone, but not with 5F/B9 clone (Gulati et al. 2013), showing 219 
opposing results for the same species. Anyway, differences in the culture medium, such as the 220 
content of FBS, the timeframe of plastic-adherent culture and the cell harvesting technique 221 
could influence the cell characteristics (Paebst et al. 2014). 222 
UCBMSCs from different species possess an intermediate phenotype that more closely 223 
resembles ES cells: Tra1-60, Tra1-81 and Oct4 are present (Reed et al. 2008; Seo et al. 2009; 224 
Raoufi et al. 2011; Mohanty et al. 2014), but conflicting data are reported for Nanog and Sox2 225 
(Reed et al. 2008; Mohanty et al. 2014), particularly in the horse.  226 
 227 
Umbilical Cord  228 
 229 
UC is routinely discarded at parturition and its extracorporeal nature facilitates isolation by 230 
eliminating the invasive and discomfort extraction procedures as well as patient risks that 231 
attend adult stem cell isolation. Most significantly, the comparatively large volume of UC and 232 
ease of physical manipulation theoretically increase the number of stem cells that can be 233 
extracted, which make it possible to get substantial number of cells in several passages 234 
without need of long term culture and extensive expansion ex vivo. Probably due to the 235 
possible absence of this structure at birth, because of reduction of the water and substances 236 
content towards the end of pregnancy, different authors, particularly in veterinary medicine, 237 
named interchangeably WJ or UCM. Due to this reason, in Table 4, we reported data 238 
regarding WJ and UCM MSCs together. Usually, spindle-shaped cells have been isolated; 239 
however few authors described a heterogeneous cell population (fusiform or spindle form and 240 
small round cells with large and prominent nucleus), from porcine and caprine UC, 241 
characterized by a plateau or a stationary phase (Mitchell et al. 2003; Babaei et al. 2008). In 242 
these species, such as in canine (Filioli Uranio et al. 2011) and bovine (Cardoso et al. 2012), 243 
UC cells expressed high levels of telomerase activity, and this phenomenon could explain the 244 
long term of cell culture observed by the authors. Moreover, tissue culture procedure does not 245 
alter chromosomal organization (Filioli Uranio et al. 2011; Cardoso et al. 2012; da Cunha et 246 
al. 2014). As reported above, also cell isolated from UC are negative for hematopoietic 247 
markers and express a number of antigens associated with adult MSCs (Table 4). Conflicting 248 
data are reported regarding their expression of embryonic markers. Cells from porcine, 249 
bubaline and equine UC resulted positive for pluripotency genes OCT4, NANOG, SOX2 at 250 
different culture passages (Mitchell et al. 2003; Carlin et al. 2006; Hoynowsky et al. 2007; 251 
Singh et al. 2013; Sreekumar et al. 2014). In canine, all authors agree that during in vitro 252 
passages cells lost OCT4 expression. However, while Lee et al. (2013a) stated that expression 253 
of NANOG and SOX2 is negatively correlated with the number of passages but is always 254 
present, most recently Filioli Uranio et al. (2014) showed that NANOG gene is present only 255 
in cells recovered at late gestational age. This discrepancy is likely due to different culture 256 
conditions and to different selection of cord tissue to be processed. The immature cells that 257 
retain the ability to proliferate were located close to the amniotic surface, whereas highly 258 
differentiated, non-proliferating fibroblasts were located in closer proximity to the umbilical 259 
vessels (Nanaev et al. 1997).  260 
 261 
Clinical Applications 262 
 263 
Clinical application of foetal MSCs in domestic animals had an increase in the last five years. 264 
The majority of the studies are on AFMSCs, mainly used in animal-model diseases (heart, 265 
diaphragm, trachea and tendon induced injuries in different species) (Table 5). Among tissue-266 
engineering studies in the sheep, diaphragmatic repair with a mesenchymal amniocyte-based 267 
engineered tendon led to improved structural outcomes when compared with equivalent fetal 268 
myoblast-based and acellular graft (Kunisaki et al. 2006c). Investigating the ability of 269 
AFMSCs for phenotypic conversion to vascular cells and cardiomyocytes (CM) when 270 
autotransplanted in a porcine model acute ischemic myocardium (AMI), MSCs were able to 271 
transdifferentiate to cells of vascular cell lineages but not to CM. Thus, porcine AFMSCs may 272 
require further ex vivo re-programming to be suitable for therapeutic use in AMI (Sartore et 273 
al. 2005). On the other hand, intramuscular injection of porcine AFMSCs reduced scar size 274 
and preserved heart function after induced myocardial infarction in mice (Peng et al. 2014). 275 
Only in the horse AFMSCs were used, combined with PRP (plateled rich plasma), to treat 276 
spontaneous decubitus ulcers (Iacono et al. 2012c). When comparing different treatments 277 
(aloe gel, PRP alone, MSCs+PRP), mean regression of ulcer treated with MSCs+PRP was 278 
higher than others. 279 
Despites animal UC cells molecular characterization, in vitro differentiation and their 280 
immunosuppressive effects on T-cells in vitro (Cardoso et al. 2012), there are sparse 281 
literatures documenting their therapeutic applications (Table 5). Equine UCBMSCs were 282 
successfully used as allogenic therapy in race-horses with spontaneous tendon lesions (Kang 283 
et al. 2013; Van Loon et al. 2014). Canine UCBMSCs and WJMSCs were mainly applied to 284 
treat induced spinal cord injuries or bone defects. Dog WJMSCs can replace adult MSCs in 285 
clinical bone engineering procedures (Kang et al. 2012) and promote functional recovery in 286 
spinal cord injured dogs after allogenic transplantation (Ryu et al. 2012). Caprine WJMSCs 287 
allogenic (Azari et al. 2011) and xenogenic transplantation (Pratheesh et al. 2014) in a rabbit 288 
model, could be successfully performed for treating induced skin wounds. In not-treated 289 
wounds, incomplete re-epithelialization and thick granulation tissue were observed, whereas, 290 
in treated wounds intact skin with complete re-epithelialization, no inflammation, and thin 291 
granulation tissue were seen. Furthermore, in both studies, histomorphological evaluation 292 
demonstrated better epithelization, lower neovascularisation, and denser collagen fibres in 293 
treated wounds.  294 
Although implantation of human AMSCs into animals resulted in successful and persistent 295 
engraftment in multiple organs and tissues (Lindenmair et al. 2012), their application in 296 
veterinary medicine are still limited (Table 5). In fact, except for a study to enhance cervical 297 
interbody fusion in an ovine model (Goldschlader et al. 2011) and histological and functional 298 
improvement after transplantation in a porcine model of chronic myocardial ischemia 299 
(Kimura et al. 2012), AMSCs were only applied in equine spontaneous tendon injuries. 300 
Allogenic transplantation resulted in a quick reduction in tendon size and ultrasonographic 301 
cross-sectional area (Lange-Consiglio et al. 2012) and the re-injury rate was lower compared 302 
to autologous BMMSCs transplantation (Lange-Consiglio et al. 2013c). The hypothesis of a 303 
paracrine mechanism of tendon repair when AMSCs are injected was confirmed in vivo; 304 
when horse tendon injuries were treated with conditioned medium, a lower rate of re-injuries 305 
was observed compared to untreated animals (Lange-Consiglio et al. 2013b). AMSCs and 306 
their conditioned medium were recently considered candidates for equine uterine regenerative 307 
therapy, due to their ability to increase in vitro endometrial cell proliferation rate (Corradetti 308 
et al. 2014). So far, AMSCs are promising not only for cell-based therapies, but also for novel 309 
therapeutic biological cell-free products.  310 
 311 
Conclusion 312 
Altogether, these studies offer authoritative views on markers expression and therapeutic 313 
potential of MSCs from foetal tissues and fluids in domestic animals. These sources are easily 314 
available and relatively abundant, so MSCs may have an attraction compared to other 315 
established SCs in different clinical approaches. Anyway, more clinical applications are 316 
needed to fully understand their properties and to establish the future clinical use in the 317 
treatment of various diseases. 318 
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Table 1. AMSCs characterization. 689 
Species Phenotype In vitro differentiation Ref. 
Sheep ICC: Oct4+,TERT+ 
 
Osteogenic, myogenic (Mauro et al. 2010) 
 
Horse FCA: CD44+,CD90+,CD14+,CD45+,CD29-,MHCI-,MHCII- 
ICC: cKit+,Oct4+,CD105+  
Adipogenic, chondrogenic, 
osteogenic 
(Coli et al. 2011) 
 
    
 RT-PCR: OCT4+,SOX2+,NANOG+,CD105+,CD34- Adipogenic, chondrogenic, 
osteogenic 
 
(Violini et al. 2012) 






(Lange-Consiglio et al. 
2012) 





(Seo et al. 2013) 
 AP+ 






(Lange-Consiglio et al. 
2013a) 
 FCA: Oct4+,SSEA4+,cMyc+,CD34- 
RT-PCR: CD29+,CD44+, CD166+, CD105+, CD34- 
MHCI+,MHCII- 
 
 (Corradetti et al. 2014) 





(Filioli Uranio et al. 2011) 






(Park et al. 2012) 
 RT-PCR: OCT4+,NANOG-,CD29+,CD44+,CD184+,CD34-, 
CD45-,DLA79-,DLA88-,DLA-DRA1-,DLA-DQA1- 
 
Osteogenic, neurogenic (Filioli Uranio et al. 2014) 
    






(Iacono et al. 2012b) 
 
 FCA: CD73+,CD90+,CD34±,CD45-,CD79- Adipogenic, chondrogenic, 
osteogenic 








Osteogenic (Mann et al. 2013) 




(Corradetti et al. 2013) 
+: positive, -: negative; ±: weakly positive; ICC: immunocytochemistry.690 
Table 2. AFMSCs characterization. 691 
Species Phenotype In vitro differentiation Ref. 
Sheep ICC: FSP+,CD31-,Vimentin+,SMA+,Desmin-,CK8+,CK18+ 
 
   (Kaviani et al. 2001) 
 ICC: Vimentin+,CK8+,CK18+,CD31- Chondrogenic (Kunisaki et al. 2006a) 
 
    Chondrogenic (Kunisaki et al. 2006b) 
 
 FCA: CD29+,CD44+,CD90±,CD105±,CD31- Adipogenic, 
osteogenic 
 
(Kunisaki et al. 2007) 
 
 ICC: Oct4+,TERT+ Osteogenic, myogenic (Mauro et al. 2010) 
 




(Shaw et al. 2011) 
 FCA: CD29+,CD44+,CD105+,CD166+,CD31-    (Gray et al. 2012) 
 ICC: SSEA4+,STRO4+,CD29+,CD44+,CD166+ 
RT-PCR: OCT4+,NANOG+,SOX2+ 
 
   (Weber et al. 2012) 
 ICC: TERT+,Sox2+,Nanog+ Osteogenic (Colosimo et al. 2013a) 









(Colosimo et al. 2013b)  





Osteogenic (Di Tomo et al. 2013)  














   (Sartore et al. 2005) 




(Zheng et al. 2009) 
 
 RT-PCR: OCT4+,SOX2+,THY+ Neurogenic (Zheng et al. 2010) 









(Chen et al. 2011) 
 FCA: CD44+,CD90+,CD31-,CD4a-   (Peng et al. 2014) 
 





(Lovati et al. 2011) 
 
 
 FCA: CD44+,CD90+,CD105+,CD14-,CD34-,CD45-,CD73- Adipogenic, 
chondrogenic, osteogenic 
(Iacono et al. 2012a) 
 
 
    Adipogenic, 
chondrogenic, osteogenic 
 
(Iacono et al. 2012c) 
 
 AP+ 


























(Fernandes et al. 2012) 
 












    Neurogenic (Kim et al. 2014) 
 
 
Cat FCA: CD44+,CD90+,CD105+,CD34±,CD14-,CD45-,CD73- Adipogenic, 
chondrogenic, osteogenic 

















   (Yadav et al. 2012) 
 
 













(Corradetti et al. 2013) 





(Gao et al. 2014) 





(Rossi et al. 2014) 
+: positive, -: negative; ±: weakly positive; ICC: immunocytochemistry. 692 
  693 
Table 3. UCBMSCs characterization. 694 
Species Phenotype In vitro differentiation Ref. 
Sheep    Chondrogenic (Fuchs et al. 2005) 
 
    Adipogenic, chondrogenic, 
osteogenic 
 
(Jager et al. 2006) 
 FCA: CD44+,CD38-,CD45-,CD41/61-    (Fadel et al. 2011) 
 
Horse    Adipogenic, chondrogenic, 
osteogenic 
 








(Guest et al. 2008) 




(Reed and Johnson, 2008) 
 
    Chondrogenic (Berg et al. 2009) 
  





(Schuh et al. 2009) 
 
    Osteogenic (Toupadakis et al. 2010) 
 
    Osteogenic (Figueroa et al. 2011) 
 
 FCA: CD86-,MHCI-,MHCII- 
 
 (Carrade et al. 2011) 
 FCA: CD29+,CD44+,CD90+,CD86-,MHCI+,MHCII-,F6B-    (Carrade et al. 2012) 
 
    
 FCA: CD29+,CD44+,CD90+,CD79α-,MHCII- Adipogenic, chondrogenic, (De Shauwer et al. 2011) 
osteogenic 
    






(De Shauwer et al. 2012) 
    Adipogenic, chondrogenic, 
osteogenic 
 














(Kang et al. 2013) 







(De Schauwer et al. 2014) 
 










   (Paebst et al. 2014) 
Dog  Osteogenic (Jang et al. 2008) 











 FCA: CD44+,CD73+,CD90+,CD105+,CD14-,CD34-,CD45- Osteogenic (Kang et al. 2012) 






(Kumar et al. 2007) 
Cat FCA: CD9+,CD44+,CD18-,CD45- 
ICC: Vimentin+ 
Neurogenic (Jin et al. 2008) 
    
Bovine RT-PCR: OCT4+,CD73+ Adipogenic, chondrogenic, 
osteogenic 
(Raoufi et al. 2011) 
+ :positive; - : negative; ± : weakly positive; ICC: immunocytochemistry695 
Table 4. WJMSCs and UCMMSCs characterization. 696 
Species Phenotype In vitro differentiation Ref. 





qPCR: OCT4+,NANOG+,SOX2+  
 
   (Carlin et al. 2006) 





(Hoynowski et al. 2007) 
 RT-PCR: Oct4+, Sox2+  (Cremonesi et al. 2008) 
    
    Adipogenic, chondrogenic, 
osteogenic 
 
(Passeri et al. 2009) 
    Osteogenic (Toupadakis et al. 2010) 
 







(Corradetti et al. 2011) 





(Lange-Consiglio et al. 
2011) 
 





(Lovati et al. 2011) 
 RT-PCR: CaSR+  (Martino et al. 2011) 
 
 FCA: CD86-,MHCI-,MHCII-  (Carrade et al. 2011) 
 
 FCA: CD29+,CD44+,CD90+,CD86-,MHCI+,MHCII-,F6B-    (Carrade et al. 2012) 
 
 
    Adipogenic, chondrogenic, 
osteogenic 
 
(Burk et al. 2013) 
 FCA: CD29+,CD44+,CD90+,CD45-,CD73-,CD79-,CD105-, 
MCHII-,Monocyte marker- 
   (De Schauwer et al. 
2013) 
 
    




(Barberini et al. 2014) 
    






(De Schauwer et al. 
2014) 
 
 FCA: CD29+,CD44±,CD73-,CD90-,CD105-,CD14-,CD34-, 
CD45-,CD79-,MHCII- 
   (Paebst et al. 2014) 
 









   (Azari et al. 2011) 





(Pratheesh et al. 2014) 





(Filioli Uranio et al. 
2011) 
 FCA: CD44+,CD73+,CD90+,CD105+,CD14-,CD34-,CD45- 
 
Osteogenic (Kang et al. 2012) 
 





(Ryu et al. 2012) 





(Seo et al. 2012) 
 RT-PCR: CD44+,CD54+,CD61+,CD80+,CD90+,CD105+ 
 
Chondrogenic (Lee et al. 2013a) 








(Lee et al. 2013b) 
 FCA: CD29+,CD44+,CD184+,OCT4+,CD34-,CD45-, 
DLA-DRA-,DLA-DQA1-,DLA79-,DLA88- 
Osteogenic, neurogenic (Filioli Uranio et al. 
2014) 
    
Bovine RT-PCR: OCT4+,ITSN1+ Adipogenic, chondrogenic, 
osteogenic, neurogenic 
 
(Cardoso et al. 2012a) 
 
    Neurogenic (Cardoso et al. 2012b) 
 
Buffalo FCA: CD29+,CD73+,CD90+,CD105+,CD34-,CD36-,CD45- 
RT-PCR: OCT4+,NANOG+,SOX2+ 
Adipogenic, osteogenic (Singh et al. 2013) 







(Sreekumar et al. 2014) 
+ : positive; - : negative; ± : weakly positive; ICC: immunocytochemistry  697 
Table 5. Clinical applications of foetal MSCs in domestic animals. 698 
MSCs source Species Clinical application Ref. 
AM Sheep Diskectomy with bone graft 
 
(Goldschlaget et al. 2011) 
 Horse Spontaneous tendon and ligament injuries 
 
(Lange-Consiglio et al. 2012; 
2013b; 2013c) 
 
 Pig Myocardial ischemia (Kimura et al. 2012) 
 
AF Sheep Diaphragmatic repair with graft 
 
(Fuchs et al. 2004; Turner et al. 
2011) 
  Prenatal tracheal reconstruction with scaffold (Kunisaki et al. 2006b; Gray et al. 
2012) 
 
  Diaphragmatic repair 
 
(Kunisaki et al. 2006c) 
 
  Prenatal treatment with lentiviral transducted cells 
 
(Shaw et al. 2011) 
  Prenatal cell-based heart valves implantation 
 
(Weber et al. 2012) 
  Tendon injuries with nucleofected cells 
 
(Colosimo et al. 2013a) 
 Swine Cardiac ischemia 
 
(Sartore et al. 2005) 
  Myocardial infarction in mouse  (Peng et al. 2014) 
 
 Horse Spontaneous decubitus ulcers with PRP 
 
(Iacono et al. 2012c) 
UCB Horse Intra-articular injection 
 
(Carrade et al. 2011) 
  Spontaneous tendinitis of superficial digital flexor tendon 
 
(Kang et al. 2013) 
  Spontaneous tendon and ligament disorders (Van Loon et al. 2014) 
 
 Dog Spinal cord injury (Lim et al. 2007; Park et al. 2011) 
 
  Diaphyseal defect in the radius 
 
(Jang et al. 2008) 
  Bone regeneration in ectopic implantations 
 
(Byeon et al. 2010) 
 
  Segmental bone defects (Kang et al. 2012) 
WJ/UCM Swine Transplantation into rat brains (Weiss et al. 2003) 
    
  Allogeneic engraftment in the neonatal intestine 
 
(Miller et al. 2012) 
 
 Caprine Skin wounds  (Azari et al. 2011) 
 
  Skin wounds in rat (Pratheesh et al. 2014) 
 
 Horse Intra-articular injection 
 
(Carrade et al. 2011) 
 Dog Segmental bone defects (Kang et al. 2012) 
 
  Spinal cord injuries (Ryu et al. 2012) 
 699 
